AngioDynamics Bundle
How has AngioDynamics Transformed the Medical Landscape?
Discover the compelling journey of AngioDynamics, a leading medical device company that has revolutionized healthcare. From its humble beginnings in 1988 in Queensbury, New York, to its current status as a publicly traded entity, AngioDynamics has consistently pushed the boundaries of medical technology. This AngioDynamics SWOT Analysis will give you more insights into the company.
AngioDynamics' brief history is a testament to its dedication to innovation and improving patient outcomes. The company's initial focus on interventional radiology and subsequent expansion into vascular access and cancer treatment options have solidified its position in the medical technology market. Understanding the AngioDynamics company's evolution provides valuable insights for investors and industry professionals alike, highlighting its adaptability and potential for future growth.
What is the AngioDynamics Founding Story?
The AngioDynamics story began in 1988, marking its entry into the medical device industry. The company's genesis in Queensbury, New York, was strategic, leveraging the area's reputation as 'Catheter Valley,' a hub for medical device manufacturing.
The initial focus of AngioDynamics was on research and development, specifically targeting products for interventional radiology. This early emphasis set the stage for its evolution into a significant player in medical technology.
While specific founders' names aren't prominently featured in recent public records, the company's establishment was driven by the need for advanced medical devices in minimally invasive procedures. AngioDynamics initially concentrated on developing and manufacturing diagnostic catheters for non-coronary angiography and thrombolytic delivery systems. These early products were crucial, paving the way for their expansion into various medical device markets.
AngioDynamics' Founding and Early Focus
Established in 1988 in Queensbury, New York, AngioDynamics emerged in 'Catheter Valley', a region known for medical device manufacturing.
- Initially focused on research and development for interventional radiology products.
- Early products included diagnostic catheters for non-coronary angiography and thrombolytic delivery systems.
- The company's foundation was built on addressing the need for advanced medical devices in minimally invasive procedures.
- This early focus laid the groundwork for AngioDynamics' future expansion in the medical technology sector.
AngioDynamics SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of AngioDynamics?
The early years of AngioDynamics were marked by rapid growth and strategic expansion within the medical device industry. The company quickly established a presence in the market, focusing on diagnostic catheters and thrombolytic delivery systems. This period saw significant acquisitions aimed at broadening its product offerings and market reach.
Key Acquisitions
Several acquisitions played a crucial role in shaping the
Navilyst Medical Acquisition
A pivotal moment was the acquisition of Navilyst Medical in May 2012. This significantly expanded AngioDynamics' scale, doubling its share in the vascular access market. This move also strengthened its position in the peripheral vascular market, adding market-leading fluid management systems. These strategic acquisitions highlight the
Headquarters and Public Listing
In March 2010, AngioDynamics established its new headquarters in Albany, New York, while maintaining operations in Queensbury and Glens Falls, New York, where most products are designed and manufactured. The company became publicly traded on the NASDAQ stock exchange under the symbol ANGO in May 2004, marking a significant step in its evolution.
Recent Financial Performance
In fiscal year 2025, AngioDynamics has shown continued growth. Net sales for the third quarter, ending February 28, 2025, reached $72.0 million, a 9.2% increase year-over-year. The Med Tech segment saw a 22.2% increase to $31.3 million in Q3 FY2025. This growth, particularly with AlphaVac sales increasing by 161.4% and AngioVac sales by 23.1% year-over-year, underscores the success of its strategic focus.
AngioDynamics PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in AngioDynamics history?
The AngioDynamics company has marked several key milestones throughout its history, particularly in the realm of minimally invasive medical devices. These achievements reflect its commitment to innovation and its strategic focus on high-growth MedTech markets. The company's journey includes significant product launches, regulatory approvals, and strategic shifts to enhance its market position.
| Year | Milestone |
|---|---|
| December 2024 | Received FDA 510(k) clearance for the NanoKnife System for prostate tissue ablation, following the successful PRESERVE clinical study. |
| January 2025 | Initiated the AMBITION BTK RCT and Registry to generate clinical evidence for the Auryon Atherectomy System in treating below-the-knee lesions. |
| First Quarter of Fiscal Year 2025 (ending August 31, 2024) | Received CE Mark Approval in Europe for the Auryon System. |
| June 2023 | Divested the Dialysis and BioSentry businesses. |
| February 2024 | Sold its PICC and Midline product portfolios to Spectrum Vascular for $45 million. |
AngioDynamics has consistently pushed the boundaries of medical technology, introducing groundbreaking solutions. A key example is the NanoKnife System, which uses irreversible electroporation (IRE) technology. This technology is designed to treat prostate tissue and is a minimally invasive option for patients.
NanoKnife System
The NanoKnife System utilizes irreversible electroporation (IRE) technology for the surgical ablation of soft tissue, offering a non-thermal, radiation-free approach. In December 2024, the system received FDA 510(k) clearance for prostate tissue ablation, supported by positive clinical study results.
Auryon Peripheral Atherectomy Platform
The Auryon platform has shown strong performance, with double-digit year-over-year growth for 15 consecutive quarters following its launch. The system received CE Mark Approval in Europe in the first quarter of fiscal year 2025 (ending August 31, 2024), expanding its market reach.
AlphaVac F1885 System
The AlphaVac F1885 System has demonstrated safety and efficacy in treating pulmonary embolism, with peer-reviewed data showing a 35.5% clot burden reduction. This system provides a valuable tool for managing this critical condition.
Despite its innovations, AngioDynamics has faced challenges, including market downturns and competitive pressures. The company has undertaken strategic transformations, including divestitures, to streamline its operations and focus on core growth areas. Further insights into the company's approach can be found in an analysis of the Marketing Strategy of AngioDynamics.
Market Downturns
Economic fluctuations and shifts in the medical device market have presented challenges. These downturns can impact sales and require strategic adjustments to maintain financial performance.
Competitive Threats
The medical device industry is highly competitive, with numerous companies vying for market share. This competition necessitates continuous innovation and effective marketing strategies.
Strategic Divestitures
To enhance focus, AngioDynamics has divested certain product lines, such as the Dialysis and BioSentry businesses in June 2023, and the PICC and Midline product portfolios in February 2024. These moves aim to streamline operations and concentrate on high-growth areas.
AngioDynamics Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for AngioDynamics?
The AngioDynamics company has a rich history marked by strategic acquisitions, product innovations, and a focus on medical technology. Founded in 1988, the company initially concentrated on research and development before expanding into manufacturing and shipping products. AngioDynamics has evolved significantly since its inception, adapting to market changes and expanding its portfolio through various acquisitions and divestitures.
| Year | Key Event |
|---|---|
| 1988 | AngioDynamics is founded in Queensbury, New York, with a focus on interventional radiology products. |
| Early 1990s | The company begins manufacturing and shipping products, including diagnostic catheters and thrombolytic delivery systems. |
| May 2004 | AngioDynamics becomes publicly traded on the NASDAQ stock exchange under the symbol ANGO. |
| January 2007 | Acquires RITA Medical Systems, adding ablation technologies to its portfolio. |
| May 2008 | Acquires Oncobionic, expanding its offerings. |
| June 2008 | Acquires assets of Diomed, further diversifying its product line. |
| January 2009 | Acquires FlowMedica, enhancing its capabilities. |
| March 2010 | Opens new headquarters in Albany, NY. |
| May 2012 | Acquires Navilyst Medical, significantly increasing its market share in vascular access and peripheral vascular products. |
| June 2023 | Divests the Dialysis and BioSentry businesses, streamlining its focus. |
| February 2024 | Completes the sale of PICC and Midline product portfolios to Spectrum Vascular for $45 million and discontinues Radiofrequency and Syntrax products. |
| October 3, 2024 | Reports fiscal year 2025 first-quarter financial results, with net sales of $67.5 million. |
| December 2024 | Receives FDA 510(k) clearance for the NanoKnife System for prostate tissue ablation. |
| January 8, 2025 | Reports fiscal year 2025 second-quarter financial results, with pro forma net sales of $73.0 million, a 9.2% increase year-over-year. |
| February 28, 2025 | Fiscal year 2025 third quarter ends, with pro forma net sales of $72.0 million. |
| April 2, 2025 | Reports fiscal year 2025 third-quarter financial results. |
| January 1, 2026 | CPT Category I Codes for Irreversible Electroporation (IRE) for prostate and liver treatment become effective. |
Fiscal Year 2025 Outlook
AngioDynamics anticipates net sales to be in the range of $285 million to $288 million for fiscal year 2025, representing a growth of 5.3% to 6.4% over the fiscal 2024 pro forma revenue of $270.7 million. Med Tech net sales are expected to grow between 14% and 16%, while Med Device net sales are projected to remain flat.
Financial Projections
The company projects a gross margin of approximately 53% to 54% for fiscal year 2025. Adjusted EBITDA is expected to be in the range of $4.0 million to $5.0 million. AngioDynamics aims to generate positive operating cash flow in the fourth quarter of fiscal 2025.
Strategic Focus
AngioDynamics is concentrating on its MedTech segment, with strategic initiatives to accelerate the adoption of the NanoKnife System and expand its global presence. This strategy aligns with its long-term vision of providing innovative medical technologies.
Financial Health
The company anticipates ending fiscal year 2025 with approximately $55 million in cash and cash equivalents and zero debt. This financial position supports its strategic initiatives and future growth plans in the medical device industry.
AngioDynamics Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What is Competitive Landscape of AngioDynamics Company?
- What is Growth Strategy and Future Prospects of AngioDynamics Company?
- How Does AngioDynamics Company Work?
- What is Sales and Marketing Strategy of AngioDynamics Company?
- What is Brief History of AngioDynamics Company?
- Who Owns AngioDynamics Company?
- What is Customer Demographics and Target Market of AngioDynamics Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.